TCGA-MP-A4TF-01A-11R-A262-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.350
- DNA_REPAIR+0.310
- TGF_BETA_SIGNALING+0.280
- INTERFERON_ALPHA_RESPONSE+0.270
- MITOTIC_SPINDLE+0.220
- G2M_CHECKPOINT+0.170
- GLYCOLYSIS+0.160
- WNT_BETA_CATENIN_SIGNALING+0.140
- PI3K_AKT_MTOR_SIGNALING+0.130
Top 10 suppressed
- MYOGENESIS-0.400
- KRAS_SIGNALING_DN-0.330
- ALLOGRAFT_REJECTION-0.320
- IL6_JAK_STAT3_SIGNALING-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- CHOLESTEROL_HOMEOSTASIS-0.270
- OXIDATIVE_PHOSPHORYLATION-0.270
- HEDGEHOG_SIGNALING-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- COAGULATION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R337 | — | — | 0.724 |
| 2 | MDT-AP-3245 | Med | Medulloblastoma | 0.704 |
| 3 | SRR5088921 | — | — | 0.695 |
| 4 | SJEPD031236_D1.RNA-Seq | EPN | Supratentorial EPN | 0.691 |
| 5 | SRR5088920 | — | — | 0.688 |
| 6 | MDT-AP-0329 | Med | Medulloblastoma | 0.686 |
| 7 | SJEPD032426_D1.RNA-Seq | EPN | Anaplastic EPN | 0.686 |
| 8 | TCGA-H4-A2HQ-01A-11R-A180-07 | — | — | 0.684 |
| 9 | TCGA-E2-A10A-01A-21R-A115-07 | — | B | 0.679 |
| 10 | fe4a0710-a6db-4735-9d1a-113df310def6 | — | — | 0.676 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |